首頁
Cognate BioServices

7月 2026Cognate BioServices的市場佔有率分析

cognate is the premier biologics cdmo. we provide the broadest range of services for regenerative medicine, cellular immunotherapy, and cell therapy.

科學與教育 > 生物學

域名cognatebioservices.com

成立年份2002

僱員501 - 1000

年度營收$100M - $200M

Cognate BioServices

Cognate BioServices（包含公司地區）

cognatebioservices.com

查看更多網站流量與參與度資訊

Cognate BioServices截至 7月 2026 的總收入為 100M - 200M

Cognate BioServices 熱門網域產生的總收入

Cognate BioServices 熱門網域 3 年內的總收入

Cognate BioServices 熱門網域的總收入

cognatebioservices.com100M - 200M

透過銷售情報查看更多內容

Cognate BioServices的熱門網域總造訪量

了解Cognate BioServices市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

cognatebioservices.com539

透過銷售情報查看更多內容

Cognate BioServices的熱門網域平均造訪時長

分析Cognate BioServices參與度指標。

過去 3 個月平均造訪時長

子公司細目

cognatebioservices.com00:01:15

透過銷售情報查看更多內容

Cognate BioServices的熱門網域平均頁面瀏覽量

了解Cognate BioServices如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

cognatebioservices.com2.09

透過銷售情報查看更多內容

Cognate BioServices按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Cognate BioServices

这些是Cognate BioServices顶级域名使用的行业网站技术

小工具 (5)

Twemoji

付費廣告 (4)

DoubleClick

內容管理系統 (2)

WordPress

轉換與分析 (2)

Google Analytics

更多技術

7

檢視所有

新聞與訊號來自Cognate BioServices

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Piré leaves Cognatebioservices as chief legal officer and global head of sustainability.Abbasi joins from Symbotic where she served as chief human resources officer, while Piré joins from Cognate BioServices where she was chief legal officer and global head of sustainability.

新聞Cognatebioservices expands facilities to United States, Northern America, Americas.Under his leadership, Cognate grew from relative obscurity to the leading international CDMO for cell and gene therapy with revenue in excess of $120 million, and manufacturing facilities in the US, the UK and Sweden.

新聞Charles River Laboratories International, Inc. acquired Cognatebioservices for $875M on Jan 1st '21.For instance, in February 2021, Charles River Laboratories, Inc. has announced the acquisition of Cognate BioServices, Inc., a leading cell and gene therapy contract development and manufacturing organization (CDMO), which has $875 million in cash, subject to customary closing adjustments.